IGHE and asthma: The PROSPERO trial found that female asthma patients with a positive allergen-specific IgE result achieved more improvement 48 weeks after omalizumab initiation, according to one of three criteria: an annual exacerbation reduction ≥50%, improvement in ACT ≥20 points or increased FEV1 ≥ 120 mL.